synergenx semaglutide headaches on Recurrent Idiopathic Intracranial Hypertension–Related Papilledema After Abrupt Discontinuation of Semaglutide: JNO Article: https://bit.ly/JNO_recurr_IIH_GLP1RA #brain #eye #vision #research #Neurology #NeuroOphth SynergenX Launches "$250 for 250"
Description
PlexusDx personalizes your semaglutide journey to match your unique biology
In trials, Retatrutide's highest dose resulted in an impressive average weight loss of 28.3% over 80 weeks, compared to tirzepatide's 20.9% at its peak dose
Why Protein and Fiber Matter
The results of the phase 3a PIONEER TEENS study will underpin filings of the drug under the Ozempic and Rybelsus brand names before the end of 2026, and according to Novo Nordisk could become the first oral GLP-1 therapies approved for use in paediatric T2D patients
Evidence for Anti-aging Benefits of GLP-1s A growing body of research suggests GLP-1s have effects beyond weight loss and glycemic control
